Human Pilot Study - HA35 (Hyaluronan Molecular Weight 35) Dietary Supplement for Promoting Intestinal Health
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
The purpose of this study is to evaluate whether oral HA35 supplementation changes the normal intestinal bacteria, increases intestinal protection, decrease intestinal inflammation and permeability, and to assess any health benefits and confirm the safety profile of HA35.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years to 45 Years (Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Twenty healthy adult volunteers, ten with a lean BMI between 19-25 and ten with an obese BMI between 30-35, will complete this study. There will be no restriction to gender or race. Age limits will be 18-45 years for this pilot study, since ageing may affect intestinal immunity, microbiome composition, prevalence of pre-clinical disease confounders
BMI 19-25 (lean), and BMI 30-35 (obese)
Age 18-45 years old
Willingness to take oral supplement and adhere to study requirements
Oral antibiotics within 4 weeks of study initiation
History of cardiac disease, and medications for cardiac disease
Use statins and antihypertensive drugs
Inflammatory bowel disease including irritable bowel syndrome
History of intestinal surgery, excluding hernia repair and appendectomy